secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001689548-25-000100
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis ulixacaltamide Essential3 Phase 3 meets primary endpoint: 4.3 pt mADL11 improvement vs placebo (p<0.0001)
--------------------------------------------------------------------------------

- Study 1: 4.3 pt mean improvement in mADL11 at Week 8 vs 1.7 pt placebo (p<0.0001); all key secondary endpoints significant.
- Study 2 randomized withdrawal: 55% maintained response on ulixacaltamide vs 33% placebo (p=0.037, OR=2.7).
- Common TEAEs included constipation, dizziness, euphoric mood, brain fog; no deaths or drug-related serious AEs.
- Pre-NDA meeting submitted to FDA; NDA submission planned by early 2026.
- Discontinuation rates due to TEAEs: 27% ulixacaltamide vs 1.7% placebo in Study 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000100/0001689548-25-000100-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000100/prax-20251016.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000100

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer